Mortality Risk Factors in the China Dialysis Outcomes and Practice Patterns Study (DOPPS)

Xinju Zhao
Peking University People's Hospital

Qingyu Niu
Peking University People's Hospital

Zhaohui Ni
Shanghai Jiaotong University School of Medicine

Xiaonong Chen
Shanghai Jiaotong University School of Medicine

Yuqing Chen
Peking University First Hospital

Fan Fan Hou
Southern Medical University

Xinling Liang
Guangdong Academy of Medical Sciences

Junhui Zhao
Arbor Research Collaborative for Health

Brian Bieber
Arbor Research Collaborative for Health

Bruce Robinson
Arbor Research Collaborative for Health

Liangying Gan
Peking University People's Hospital

Li Zuo (✉ zuoli@bjmu.edu.cn)
Peking University People's Hospital

Research Article

Keywords: hemodialysis, all-cause mortality, risk factors, end stage kidney disease, DOPPS

DOI: https://doi.org/10.21203/rs.3.rs-445338/v1

License: ☛ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background Mortality risk for hemodialysis (HD) patients varies by country and ethnicity. Here, mortality rate and its related risk factors in Chinese HD patients from the Dialysis Outcomes and Practice Patterns Study (DOPPS) were investigated.

Methods Data from China DOPPS phase 5 (2012–2015) were used. Patients’ demographics, assigned primary causes of end stage Kidney disease (ESKD), comorbidities, dialysis prescription, laboratory values, date and cause for death were analyzed. Cox proportional hazards models were used to assess the association of patient characteristics and treatments with mortality.

Results 1427 HD patients were enrolled. The mean age was 59.4 ± 14.9 years. The median follow-up time was 1.9 (1.1–2.1) years. There was total 205 deaths with at least 103 from cardiovascular disease (50.2%). The overall mortality rate was 8.8 per 100 patient-years. In the multivariate COX model, older, serum albumin (Alb < 4g/dl, blood platelets < 100*10^9/L, pulse pressure (PP) > 63mmHg, and congestive heart failure history were independent risk factors for all-cause mortality.

Conclusions Attention should be paid to patients who were older, with lower Alb and blood platelets level, higher PP and congestive heart failure history. Our results highlighted that there might be some modifiable risk factors for patients’ survival, such as Hgb, Alb, blood platelets, and blood pressure management.

Introduction

Hemodialysis (HD) therapy is a life-saving and life-sustaining procedure that improves the life expectancy of patients with end stage Kidney disease (ESKD). However, the adjusted all-cause mortality rate was 6.5–7.9 times greater for dialysis patients than for individuals in the general population[1, 2]. Understanding the mortality risk and its influencing factors in HD patients are of great interest and value, especially those modifiable risk factors. We previously reported that the crude mortality rate for maintenance HD patients in Beijing was much lower than that in the United State[3]. However, our previous analysis only included patients from one major city in China, and lacked information about risk factors for mortality, and was limited in sample size.

Previous studies have shown that mortality rates varied remarkably among different countries and ethnic groups. The United States Renal Data Services (USRDS) 2018 annual report showed that all-cause mortality was 16.6 per 100 patient-years for American maintenance HD patients[4]. In 2017, the Annual Report of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry covered a general population of 694 million people. For patients commencing renal replacement therapy (RRT) during 2008–2012, the unadjusted 5-year patient survival probability for all RRT modalities combined was 50.8%. According to the annual survey of the Japanese Society for Dialysis Therapy Renal Data Registry, the total number of patients undergoing dialysis treatment was 339,841 at the end of 2018, and the crude annual death rate was 10.0%[5]. These countries were all developed countries, and Japan
was the only country from Asia. China is a large developing Asian country and has an increasing HD population. However, the related information we hold about Chinese HD population was lacking. It is necessary to investigate the mortality rate and risk factors for Chinese HD patients and to optimize the treatment practices for its ESKD patients. Therefore, we analyzed the data of China DOPPS phase 5 (2012–2015) to describe the overall death rate and explore modifiable risk factors for patient mortality.

**Results**

1427 HD patients were enrolled in this study. The mean age was 59.4 ± 14.9 years. The median follow-up time was 1.9 (interquartile range = 1.1, 2.1) years. According to the outcome status, we divided patients into survived and died groups, and characteristics between groups were compared (Table 1). Patients in died group differed from survived patients in many ways: for instance, they were older, with a higher proportion of catheter use, had lower Hgb and Alb. Meanwhile, died patients had higher pre-dialysis and post-dialysis diastolic blood pressure (DBP) than survived patients. Compared with survived patients, patients who died had a higher proportion of diabetes, CHF and other cardiovascular disease, cerebrovascular disease, fracture, hypertension, osteoporosis, lung disease and peripheral vascular disease (Table 1).
### Table 1
Patient Baseline Characteristics of survived and died groups

| Variables                  | Survived (n = 1222) | Died (n = 205) | All (n = 1427) | P-value |
|----------------------------|---------------------|----------------|----------------|---------|
| Age (years)                | 58.5 (49.0, 69.0)   | 70.0 (59.0, 79.0) | 60 (49, 71) | < 0.001* |
| Female (%)                 | 45.2                | 43.9            | 45             | 0.800   |
| BMI                        | 21.9 ± 3.7          | 21.8 ± 4.0      | 21.9 ± 3.7    | 0.799   |
| Vintage (years)            | 2.6 (0.8–5.5)       | 2.5 (1.0–5.0)   | 2.6 (0.9–5.4) | 0.390   |
| Diabetes                   | 25.8                | 36.1            | 27.3          | 0.008*  |
| Blood access types         |                     |                 |               |         |
| Fistula                    | 85.7                | 80.0            | 84.9          | 0.047*  |
| Catheter and others        |                     |                 |               |         |
| spKt/V                     | 1.4 ± 0.3           | 1.3 ± 0.3       | 1.4 ± 0.3     | 0.611   |
| spKt/V < 1.2 (%)           | 18                  | 18.4            | 18.4          | 0.500   |
| stdKt/V                    | 2.1 (1.8–2.2)       | 2.1 (1.9–2.3)   | 2.1 (1.8–2.3) | 0.815   |
| Albumin (g/dl)             | 3.9 ± 0.5           | 3.7 ± 0.5       | 3.9 ± 0.5     | < 0.001* |
| WBC (per 10^9/L)           | 6.0 (4.9–7.3)       | 5.8 (4.6–7.5)   | 6.0 (4.9–7.3) | 0.280   |
| Hgb (g/dl)                 | 10.5 ± 1.9          | 10.1 ± 2.0      | 10.4 ± 1.9    | 0.021*  |
| Hgb < 9 g/dl (%)           | 18.3                | 27.3            | 19.6          | 0.031*  |
| Calcium (mg/dl)            | 9.1 ± 1.0           | 9.0 ± 1.0       | 9.1 ± 1.0     | 0.7269  |
| Phosphate (mg/dl)          | 5.7 (4.6–7.2)       | 5.2 (4.2–6.7)   | 5.6 (4.6–7.2) | 0.001*  |
| iPTH (pg/dl)               | 264.2 (134.0–517.6) | 233.3 (125.5–444.7) | 259.0 (131.0–509.0) | 0.180   |
| < 3-times weekly HD (%)    | 21.4                | 20.0            | 21.23         | 0.379   |

Values are expressed as mean ± SD or median (interquartile range). BMI, body mass index; spKt/V, single-pooled Kt/V; stdKt/V, standard Kt/V; WBC, white blood cells; Hgb, hemoglobin; HD, hemodialysis; HDF, hemodiafiltration; HF, hemofiltration; BUN, blood urea nitrogen; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHF, congestive heart failure; GI, gastrointestinal.
| Variables                        | Survived (n = 1222) | Died (n = 205) | All (n = 1427) | P-value |
|----------------------------------|---------------------|----------------|---------------|---------|
| HD sub-modality                 | 90.9                | 94.6           | 91.5          | 0.134   |
| HD                              | 7.4                 | 4.4            | 7.0           |         |
| HDF                             | 0.1                 | 0.5            | 0.1           |         |
| HF                              | 1.1                 | 0              | 1.0           |         |
| Mixed                            |                     |                |               |         |
| Urine output ≥ 200 ml/day (%)    | 32.7                | 27.3           | 31.9          | 0.100   |
| pre-BUN (mg/dl)                 | 40.3 (32.8–52.7)    | 37.2 (30.6–52.6) | 39.9 (32.5– 52.6) | 0.030* |
| post-BUN (mg/dl)                | 13.5 (10.1–18.2)    | 13.2 (9.3–18.8) | 13.5 (10.0-18.4) | 0.380   |
| Sodium (mEq/l)                  | 139.1 ± 3.9         | 138.7 ± 3.6    | 139.0 ± 3.5   | 0.512   |
| Potassium (mEq/l)               | 5.0 ± 0.8           | 4.9 ± 0.9      | 5.0 ± 0.8     | 0.089   |
| pre-Weight (kg)                 | 62.0 ± 11.9         | 61.0 ± 11.5    | 61.9 ± 11.8   | 0.269   |
| post-Weight (kg)                | 59.7 ± 11.7         | 58.7 ± 11.2    | 59.6 ± 11.6   | 0.245   |
| Interdialytic weight loss       | 3.9 (2.8, 5.0)      | 3.8 (2.6, 5.1) | 3.9 (2.8-5.0) | 0.324   |
| pre-SBP (mmHg)                  | 147.9 ± 20.3        | 150.3 ± 20.7   | 148.2 ± 20.4  | 0.149   |
| pre-DBP (mmHg)                  | 79.7 ± 12.4         | 77.2 ± 12.6    | 79.4 ± 12.5   | 0.009*  |
| post-SBP (mmHg)                 | 140.7 ± 22.7        | 141.8 ± 21.5   | 140.9 ± 22.6  | 0.544   |
| post-DBP (mmHg)                 | 78.7 ± 12.5         | 75.6 ± 13.0    | 78.3 ± 12.6   | 0.002*  |
| pre-Pulse                       | 76.4 ± 9.3          | 75.2 ± 10.6    | 76.2 ± 9.5    | 0.126   |
| post-Pulse                      | 77.2 ± 10.2         | 75.8 ± 10.7    | 77.0 ± 10.2   | 0.113   |
| Comorbidities (%)               |                     |                |               |         |
| CHF                             | 21.8                | 36.1           | 23.8          | < 0.001*|
| Calciphylaxis                   | 7.7                 | 9.8            | 8.0           | 0.222   |
| Cancer                          | 3.4                 | 6.3            | 3.9           | 0.102   |

Values are expressed as mean ± SD or median (interquartile range). BMI, body mass index; spKt/V, single-pooled Kt/V; stdKt/V, standard Kt/V; WBC, white blood cells; Hgb, hemoglobin; HD, hemodialysis; HDF, hemodiafiltration; HF, hemofiltration; BUN, blood urea nitrogen; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHF, congestive heart failure; GI, gastrointestinal.
During the follow-up period, 205 patients died. The overall mortality rate was 8.8 per 100 patient-years. Main causes of death including: cardiovascular disease (105, 51.2%), infection (33, 16.1%, Table 2). Other causes included malignant disease (19, 9.3%), gastrointestinal (8, 3.9%), metabolic (6, 2.9%), liver disease (2, 1.0%) and unknown (32, 15.6%).

| Variables                        | Survived (n = 1222) | Died (n = 205) | All (n = 1427) | P-value |
|----------------------------------|---------------------|---------------|----------------|---------|
| Other cardiovascular disease     | 19.5                | 29.8          | 21.0           | 0.003*  |
| Carpal tunnel syndrome           | 1.1                 | 2.4           | 1.2            | 0.203   |
| Cerebrovascular disease          | 12.7                | 24.4          | 14.4           | < 0.001*|
| Cirrhosis of the liver           | 1.1                 | 2.4           | 1.3            | 0.174   |
| Diabetes                         | 25.9                | 36.1          | 27.3           | 0.009*  |
| Fracture                         | 1.9                 | 5.4           | 2.4            | 0.008*  |
| GI Bleeding                      | 2.5                 | 2.0           | 2.4            | 0.895   |
| Hepatitis                        | 12.3                | 16.1          | 12.8           | 0.313   |
| Hypertension                     | 85.9                | 80.5          | 85.1           | 0.048*  |
| Hyperlipidemia                   | 33.6                | 36.6          | 34.0           | 0.569   |
| Lung disease                     | 4.0                 | 10.2          | 4.9            | < 0.001*|
| Neurologic disease               | 2.2                 | 3.4           | 2.4            | 0.573   |
| Osteoporosis                     | 27.0                | 39.0          | 28.7           | 0.002*  |
| Peripheral vascular disease      | 7.9                 | 15.1          | 9.0            | 0.003*  |
| Parathyroid Surgery              | 2.4                 | 0             | 2.0            | 0.068   |
| Peripheral Neuropathy            | 9.5                 | 10.2          | 9.6            | 0.846   |
| Psychiatric Disorder             | 2.0                 | 2.4           | 2.0            | 0.900   |
| Recurrent Cellulitis             | 1.5                 | 3.4           | 1.8            | 0.134   |

Values are expressed as mean ± SD or median (interquartile range). BMI, body mass index; spKt/V, single-pooled Kt/V; stdKt/V, standard Kt/V; WBC, white blood cells; Hgb, hemoglobin; HD, hemodialysis; HDF, hemodiafiltration; HF, hemofiltration; BUN, blood urea nitrogen; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHF, congestive heart failure; GI, gastrointestinal.
Table 2
The distribution of primary causes of death

| Causes of deaths       | Numbers (%) |
|------------------------|-------------|
| Cardiac/Vascular       | 105 (51.2)  |
| Liver Disease          | 2 (1.0)     |
| Infection              | 33 (16.1)   |
| Gastrointestinal       | 8 (3.9)     |
| Metabolic              | 6 (2.9)     |
| Other                  | 19 (9.3)    |
| Unknown                | 32 (15.6)   |

We use univariate COX regression analysis to select variables related to all-cause mortality from proposed clinically relevant ones (Table 3). Variables with P < 0.15 were entered as possible factors in the multivariate COX regression model. We found that age, Alb, blood platelets, history of CHF and PP were related to all-cause mortality in the final model (Table 4). For each 10-years increasing of age, the risk of all-cause mortality rose by 52% (HR = 1.52, 95%CI: 1.35–1.71). Compared with Alb ≥ 4.0 g/dl, patients with Alb in 3.5–3.9 and < 3.5 g/dl had an increased risk of death after adjustment (HR = 1.50, 95%CI: 1.10–2.11 and HR = 2.45, 95%CI: 1.65–3.63, respectively). Meanwhile, low blood platelets (< 100*10^9/L) were related to a higher death rate (HR = 1.97, 95%CI: 1.42–2.72) than normal blood platelets (100–299*10^9/L). Patients who had a history of CHF (HR = 1.57, 95%CI: 1.16–2.11) tend to have a higher mortality risk than patients without this comorbidity. Patients with higher PP (≥ 63mmHg) had a 1.41-fold higher risk for all-cause mortality (95% CI, 1.01–1.96; P = 0.042).
| Variables                                                                 | Hazard ratios | 95% CI       | P value |
|--------------------------------------------------------------------------|---------------|--------------|---------|
| Age                                                                      | 1.053         | 1.041–1.065  | < 0.001 |
| ESKD causes (CGN as reference)                                           |               |              |         |
| Diabetic nephropathy                                                     | 2.211         | 1.546–3.164  | < 0.001 |
| Hypertension                                                             | 1.822         | 1.205–2.755  | 0.005   |
| Others                                                                   | 1.465         | 0.99–2.167   | 0.056   |
| Albumin                                                                  | 0.453         | 0.363–0.567  | < 0.001 |
| Blood calcium                                                            | 0.842         | 0.724–0.979  | 0.026   |
| Blood glucose                                                            | 1.001         | 1.000–1.003  | 0.053   |
| Hemoglobulin                                                             | 0.902         | 0.841–0.967  | 0.004   |
| Phosphorus                                                               | 0.907         | 0.841–0.977  | 0.010   |
| Potassium                                                                | 0.844         | 0.713–0.998  | 0.047   |
| Creatinine                                                               | 0.854         | 0.816–0.894  | < 0.001 |
| Platelet                                                                 | 0.996         | 0.993–0.998  | < 0.001 |
| Kt/V < 1.2 (≥ 1.2 as reference)                                          | 1.443         | 0.967–2.153  | 0.073   |
| Systolic blood pressure-pre-dialysis                                     | 1.005         | 0.998–1.012  | 0.149   |
| Diastolic blood pressure-pre-dialysis                                    | 0.985         | 0.974–0.997  | 0.014   |
| Diastolic blood pressure-post-dialysis                                   | 0.983         | 0.972–0.995  | 0.004   |
| Pulse pressure                                                           | 1.013         | 1.005–1.021  | 0.001   |
| Pulse-pre-dialysis                                                       | 0.987         | 0.972–1.003  | 0.104   |
| Pulse-post-dialysis                                                      | 0.989         | 0.974–1.003  | 0.127   |
| Blood access type (fistula as reference)                                 | 1.812         | 1.282–2.562  | < 0.001 |
| Comorbidities (yes vs. no)                                               |               |              |         |
| Diabetes                                                                 | 1.647         | 1.234–2.196  | < 0.001 |
| Coronary arterial disease                                               | 2.009         | 1.517–2.661  | < 0.001 |
| Congestive heart failure                                                | 1.965         | 1.476–2.616  | < 0.001 |

Values are expressed as mean ± SD or median (interquartile range). ESKD, end stage kidney disease; Kt/V, Kt/Vurea.
| Variables                          | Hazard ratios | 95% CI          | P value  |
|-----------------------------------|---------------|-----------------|----------|
| Cancer                            | 1.766         | 1.007–3.099     | 0.047    |
| Other cardiovascular disease      | 1.596         | 1.182–2.154     | 0.002    |
| Carpal tunnel syndrome            | 1.979         | 0.815–4.808     | 0.132    |
| Cerebrovascular disease           | 2.035         | 1.479–2.802     | <0.001   |
| Cirrhosis of the liver            | 2.044         | 0.841–4.964     | 0.114    |
| Fracture                          | 2.371         | 1.291–4.354     | 0.005    |
| hepatitis                         | 1.335         | 0.919–1.938     | 0.129    |
| Lung disease                      | 2.464         | 1.568–3.873     | <0.001   |
| Osteoporosis                      | 1.525         | 1.150–2.022     | 0.003    |
| Peripheral vascular disease       | 1.945         | 1.326–2.852     | <0.001   |
| Recurrent Cellulitis              | 2.404         | 1.131–5.111     | 0.023    |

Values are expressed as mean ± SD or median (interquartile range). ESKD, end stage kidney disease; Kt/V, Kt/Vurea;
Table 4
Multivariate Cox regression model of All-Cause Mortality in China DOPPS5 patients

| Variables                        | Hazard ratios | 95% CI       | P value   |
|----------------------------------|---------------|--------------|-----------|
| Age (per 10 years)               | 1.52          | 1.35–1.71    | <0.001*   |
| Albumin (g/dl)                   |               |              |           |
| ≥ 4.0                            | 1.50          | 1.10–2.11    | <0.001*   |
| 3.5−3.9                          | 2.45          | 1.65–3.63    |           |
| < 3.5                            |               |              |           |
| Blood platelets (10^9/L)         |               |              |           |
| 100–299                          | 1.97          | 1.42–2.72    | 0.441     |
| < 100                            | 0.61          | 0.18–2.13    |           |
| ≥ 300                            |               |              |           |
| Congestive heart failure (yes vs. no) | 1.57          | 1.16–2.11    | 0.004*    |
| Pulse pressure (mmHg)            |               |              |           |
| ≤ 63                             | 1.41          | 1.01–1.96    |           |
| > 63                             |               |              |           |

Discussion

In this large prospective study of 1,427 Chinese HD patients, we reported the all-cause mortality rate and explored related risk factors. The overall mortality rate was 8.8 per 100 patient-years in our patients. Cardiovascular death was the leading cause of death, which account for more than half of all deaths. Patients that were older, with lower Alb, blood platelets, higher PP and had a history of CHF had a higher risk of all-cause mortality.

We reported a lower overall mortality rate compared with other western DOPPS countries, such as North America (14.3 per 100 patient-years) and Europe countries (13.1 per 100 patient-years)[9]. But it was a little higher than that in Japan (7.87 per 100 patient-years)[10]. Prior DOPPS analyses noted that many beneficial dialysis practices (such as high use of arteriovenous fistula, longer or more frequent dialysis sessions, more effective volume management, good patient compliance, mineral and bone disorder control) were more common in Japan than in other countries[11]. However, in European and North American countries, kidney transplantation was more common among ESKD patients than Asian countries, such as China and Japan. In other words, many healthier and younger patients have opted for
kidney transplantation instead of maintenance dialysis treatment in those countries. Therefore, transplantation may deplete the dialysis pool of healthier patients in North America and Europe, but not in China and Japan[11]. Although this may have impact on mortality rate among countries, mortality rate differences among countries may still exist after this factor adjusted.

Some widely recognized risk factors found in our results were consistent with previous researches, such as aging, low Alb, comorbidities. Not surprisingly, aging was known to be a significant risk factor for death. And the guideline of Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that the optimal serum Alb level of chronic kidney disease (CKD) patients was equal to or greater than the lower limit of the normal range (approximately 4.0 g/dL)[12]. We had 42.0% of our patients with serum Alb ≥ 4g/l, and 83.6% patients ≥ 3.5g/l. Patients with Alb ≥ 4g/l also have survival benefits, compared with patients with Alb in 3.5–3.9 g/l. Serum Alb was regarded as the reflection of visceral protein stores, so it can act as a marker of protein malnutrition. Malnutrition was a strong contributor for increasing mortality in HD patients[13, 14]. Deaths due to cardiovascular and infectious causes were increased with malnutrition and hypoalbuminemia[15, 16]. Therefore, for most patients, they should try to make serum Alb meet the target of 4 g/l, and for patients with Alb < 3.5g/l, special attention should be paid to improving their nutritional status. Comparing the clinical data of the 2 groups of patients, we found that patients who died combined with more comorbidities than those who survived. In the COX model, patients with a history of CHF had higher mortality risk. As more than half of our patients died from cardiovascular causes, patients with a history of cardiovascular disease have a higher risk of death than other patients.

In our results, patients with low platelet counts (< 100*109/L) had a higher risk of all-cause mortality. Thrombocytopenia may have serious consequences, such as increasing the risk of internal and external bleeding, delaying in wound healing and coagulation defects. Previous studies have reported that thrombocytopenia was associated with an increased risk of all-cause death and cardiovascular death in general populations and patients with lung disease[17–19]. In one study about the association about mean platelet volume (MPV) and mortality in incident HD patients, the author also showed that lower baseline platelet counts were associated with higher mortality risk across all multivariable models, which was in line with our findings[20]. Furthermore, there was a prothrombotic adverse drug reaction called Heparin-induced thrombocytopenia (HIT)[21]. Heparin is a common anticoagulant used during HD period to prevent clotting. Some patients may produce platelet-activating antibodies when they received heparin[22], and show unusual clinical features, such as thrombocytopenia, sometimes accompanied by disseminated intravascular coagulation and microvascular thrombosis. Several studies showed that HD patients with HIT were at a higher risk of cardiovascular mortality and arteriovenous fistula thrombosis than patients without HIT[23, 24].

And high PP was an independent predictor of all-cause mortality. Compared with PP < 63mmHg, PP ≥ 63mmHg was associated with a 64.8% increase in hazard ratio for death. Regarding blood pressure control, PP was not widely considered as a risk factor in ESKD patients. But several studies reported that PP was associated with all-cause mortality and/or cardiovascular mortality in HD patients[25, 26].
Meanwhile, cardiac dysfunction was a widespread problem in ESKD patients, and cardiovascular death was the major cause in those patients. Elevated PP was usually due to increased central aortic stiffness and accompanied by increased pulse-wave velocity. Said et al found that PP was associated with an increased risk of developing cardiovascular disease and cardiovascular mortality in a large community-based population[27]. Elevated pressure during systole induce left ventricular hypertrophy, then lead to left ventricular failure, whereas lower pressure throughout diastole had the possibility to limit coronary perfusion and lead to ischemia[25]. This may contribute to the high prevalence of cardiovascular disease in ESKD patients[28].

Overall, the mortality rate of our HD patients was comparatively low compared with other countries. Among China and other countries, especially developed countries, there were obvious differences in race, lifestyle, economic status, medical insurance policies and so on. Whether the risk of mortality is affected by these factors and how they affect need further investigation. Therefore, it was important to explore the risk factors related to death in Chinese HD patients and the modifiable dialysis patterns.

However, our study had several limitations. Firstly, this is an observational study which might has inherent shortcomings such as selection bias and confounding factors. Secondly, the limited number of deaths in our study makes it impossible for us to perform some more detailed subgroup analysis. Thirdly, the China DOPPS study only included patients from three major cities. We didn’t include patients receiving HD treatment in smaller cities or rural areas, and their conditions may be worse than what we reported. Therefore, the results can not represent for the whole country. Even though, the results of this study have irreplaceable significance for us to understand the current situation of Chinese HD patients and to explore modifiable practice patterns to improve patients’ survival.

In conclusion, results in this study were important and complement to previous findings and added new knowledge to the understanding of mortality risks for prevalent HD patients globally. Our analysis highlighted that there were some modifiable risk factors for Chinese patients’ survival. Attention should also be paid to patients who were older, with lower Alb, low platelet counts, higher PP, and had a history of CHF.

**Materials And Methods**

**Study design and subjects**

The DOPPS is an international prospective cohort study of in-center HD patients ≥ 18 years of age [6, 7]. Our previous works also described the methodology for the China DOPPS[8]. The current study includes patients selected for China DOPPS phase 5 (2012 to 2015).

Demographic and clinical characteristics were abstracted from medical records using a web-based data collection tool. Death events and reasons were recorded during follow-up period. The study was approved by the Ethics Committee of Peking University People’s Hospital (ethical approval number: 2018PHB028-01). All patients signed the written informed consent. The authors confirm that all the methods used in
this study comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration.

**Statistical analysis**

Baseline characteristics were reported as continuous or categorical variables. Normally distributed continuous variables were presented as mean and standard deviation (SD), otherwise, expressed as median (25th, 75th). Crude mortality rates were estimated as the number of deaths per 100 patient-years. Patients were divided into 2 groups, survived or died. Differences in baseline data between survived and died groups were evaluated by using independent sample t-test or Wilcoxon rank-sum test respectively. Differences in categorical variables between 2 groups were estimated by using chi-square test.

We examined proposed clinically relevant variables by univariate Cox regression models, and relatively significant variables (P < 0.15) were added into multivariate Cox regression analysis. The variables included in the multivariate COX regression were age, vascular access, pulse pressure (PP), serum albumin (Alb), hemoglobin (Hgb), platelet counts, spKt/V, serum corrected calcium, phosphate, comorbidities ((congestive heart failure, CHF) cancer, other cardiovascular disease, cerebrovascular disease, fracture, history cirrhosis of the liver, diabetes, hypertension, hepatitis, lung disease, peripheral vascular disease). PP was defined as the difference value of the mean pre-dialysis systolic blood pressure and the mean diastolic blood pressure. The PHREG procedure based on the Cox proportional hazards model were used to analysis association of patient characteristics with death. Patients from the same facility tend to have similar practice patterns, so we accounted for facility clustering using a robust sandwich estimator of the covariance. After adjustment, age, serum Alb level, platelet counts, comorbidities (CHF) and PP were significant and included in the final COX model.

We converted continuous variables considered as risk factors of all-cause mortality in final Cox model into categorical variables to investigate the differences in death risk among subgroups of each variable. Alb was divided into 3 groups by < 3.5g/l, 3.5-3.9g/l, and ≥ 4.0g/l; platelets counts were divided into 3 groups by < 100*10⁹/l, 101–299*10⁹/l, ≥ 300*10⁹/l; and PP were divided into 2 groups by < 63 mmHg and ≥ 63mmHg.

We performed MI procedure to impute the missing data, and continuous and categorical variables were imputed by fully conditional specification (FCS) regression and logistic regression, respectively. After 25 steps of imputation, 25 data sets were combined for the final analysis of Cox regression model. Percentages of missing for most variables were < 10%, except for Kt/V (37.8%) and transferrin saturation (40.6%). P value < 0.05 was seen as statistically significant. Statistical analysis was performed with SAS, version 9.4 (SAS institute, Cary, NC; USA), and the forest plot of subgroup analysis were performed by R software, version 3.2.3.

**Declarations**

**Acknowledgments**
The Dialysis Outcomes and Practice Patterns Study (DOPPS) Program in China is supported by Vifor Fresenius Renal Pharma, Sanofi Renal, Nipro Trading (Shanghai) Co., Ltd, 3SBio Inc., B.Braun, CEMMA MEDICAL. All of them had no role in study design; collection, analysis, and interpretation of data; writing the report; and all support was provided without restrictions on publications.

**Conflict of Interest Statement**

None declared.

**Authors’ Contributions**

Conception and design of research: XZ, LZ

Analyzed data: XZ, QN

Interpreted results of experiments: XZ, QN, LG, LZ

Prepared figures: XZ

Drafted manuscript: XZ, QN, LG

Edited and revised manuscript: ZN, XC, YC, FFH, XL, LZ, JZ, BB, BR

Approved final version of manuscript: LG, LZ

**Funding**

This article was supported by National Natural Science foundation of China (No 81870524) and Capital Clinical Characteristics Application Program (No Z131107002213122). The grant recipients are Li Zuo and Liangying Gan.

**References**

1. Hall YN, Sugihara JG, Go AS et al. Differential mortality and transplantation rates among Asians and Pacific Islanders with ESRD. J Am Soc Nephrol. 2005;16:3711-3720

2. de Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302:1782-1789

3. Cheng X, Nayyar S, Wang M et al. Mortality rates among prevalent hemodialysis patients in Beijing: a comparison with USRDS data. Nephrol Dial Transplant. 2013 Mar;28:724-32

4. United States Renal Data System. 2018 annual data report: an overview of the epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2018
5. Nitta K, Goto S, Masakane I et al. Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality.

6. Young EW, Goodkin DA, Mapes DL et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study. Kidney International 2000;57:74-81

7. Pisoni RL, Gillespie BW, Dickinson DM et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004;44:7-15

8. Zhao X, Niu Q, Gan L et al. Baseline data report of the China Dialysis Outcomes and Practice Patterns Study (DOPPS). Sci Rep 2021; 11(1): 873.

9. Stirnadel-Farrant HA, Karaboyas A, Cizman B et al. Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions-A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int Rep 2019;4:864-872

10. Tsujimoto Y, Tsutsumi Y, Ohnishi T et al. Low Predialysis Plasma Calculated Osmolality Is Associated with Higher All-Cause Mortality: The Japanese Dialysis Outcomes and Practice Patterns Study (J-DOPPS). Nephron 2020;144:138-146

11. Robinson BM, Akizawa T, Jager KJ et al. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet 2016;388:294-306

12. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000;35:1-140

13. Mekki K, Remaoun M, Belleville J et al. Hemodialysis duration impairs food intake and nutritional parameters in chronic kidney disease patients. Int Urol Nephrol 2012;44:237-244

14. Kalantar-Zadeh K, Kopple JD, Block G et al. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001;38:1251-1263

15. Iorember FM. Malnutrition in Chronic Kidney Disease. Front Pediatr 2018;6:161

16. V SM, Aguiar L, Dias C et al. Predictors of nutritional and inflammation risk in hemodialysis patients. Clin Nutr 2020;39:1878-1884

17. Fawzy A, Anderson JA, Cowans NJ et al. Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD. Respiratory research 2019;20:86

18. Bonaccio M, Di Castelnuovo A, Costanzo S et al. Age- and sex-based ranges of platelet count and cause-specific mortality risk in an adult general population: prospective findings from the Moli-sani study. Platelets 2018;29:312-315

19. Vinholt PJ, Hvas AM, Frederiksen H et al. Platelet count is associated with cardiovascular disease, cancer and mortality: A population-based cohort study. Thrombosis research 2016;148:136-142

20. Kim S, Molnar MZ, Fonarow GC, et al. Mean platelet volume and mortality risk in a national incident hemodialysis cohort. Int J Cardiol 2016; 220: 862-70.

21. Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017;15:2099-2114
22. Liu CC, Chou LP, Chen TS et al. Significant association of anti-platelet factor 4/heparin antibody with cardiovascular disease in hemodialysis patients: a longitudinal 7-year study. Int Urol Nephrol 2018;50:2289-2297

23. Matsuo T, Wanaka K, Walenga JM. Evaluation of circuit and AV fistula clotting and detection of anti-PF4/heparin complex antibodies in hemodialysis patients suspected of having heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2013;19:73-78

24. Pena de la Vega L, Miller RS, Benda MM et al. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc 2005;80:995-1000

25. Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002;287:1548-1555

26. Tozawa M, Iseki K, Iseki C et al. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney international 2002;61:717-726

27. Said MA, Eppinga RN, Lipsic E et al. Relationship of Arterial Stiffness Index and Pulse Pressure With Cardiovascular Disease and Mortality. J Am Heart Assoc 2018;7(2)

28. Fang W, Yang X, Bargman JM et al. Association between pulse pressure and mortality in patients undergoing peritoneal dialysis. Perit Dial Int 2009;29:163-170